395 related articles for article (PubMed ID: 32343472)
1. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
Chiu WN; Hung CH; Lu SN; Chen MY; Tung SY; Wei KL; Lu CK; Chen CH; Hu TH; Hu JH; Chen WM; Chang TS
J Viral Hepat; 2020 Sep; 27(9):866-872. PubMed ID: 32343472
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
Shin HD; Song IH; Lee SH; Kim HS; Lee TH; Eun HS; Kim SH; Lee BS; Chae HB; Kim SH; Song MJ; Ko SY; Kim SB
Korean J Gastroenterol; 2024 Mar; 83(3):111-118. PubMed ID: 38522854
[TBL] [Abstract][Full Text] [Related]
3. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
Liu CH; Yang SS; Peng CY; Lin WT; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
J Viral Hepat; 2020 Jun; 27(6):568-575. PubMed ID: 31981264
[TBL] [Abstract][Full Text] [Related]
4. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.
Huang CF; Kuo HT; Chang TS; Lo CC; Hung CH; Huang CW; Chong LW; Cheng PN; Yeh ML; Peng CY; Cheng CY; Huang JF; Bair MJ; Lin CL; Yang CC; Wang SJ; Hsieh TY; Lee TH; Lee PL; Wu WC; Lin CL; Su WW; Yang SS; Wang CC; Hu JT; Mo LR; Chen CT; Huang YH; Chang CC; Huang CS; Chen GY; Kao CN; Tai CM; Liu CJ; Lee MH; Tsai PC; Dai CY; Kao JH; Lin HC; Chuang WL; Chen CY; Tseng KC; Yu ML
Sci Rep; 2021 Dec; 11(1):23473. PubMed ID: 34873250
[TBL] [Abstract][Full Text] [Related]
5. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
Ding YJ; Lu CK; Chen WM; Tung SY; Wei KL; Shen CH; Hsieh YY; Yen CW; Chang KC; Chiu WN; Hung CH; Lu SN; Chang TS
J Gastroenterol Hepatol; 2021 Oct; 36(10):2911-2916. PubMed ID: 33978973
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
7. Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.
Kim NG; Kullar R; Khalil H; Saab S
J Viral Hepat; 2020 Aug; 27(8):762-769. PubMed ID: 32386099
[TBL] [Abstract][Full Text] [Related]
8. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
Chen WM; Wei KL; Tung SY; Shen CH; Chang TS; Yen CW; Hsieh YY; Chiu WN; Hu JH; Lu SN; Hung CH
J Formos Med Assoc; 2020 Nov; 119(11):1593-1600. PubMed ID: 32839045
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
[TBL] [Abstract][Full Text] [Related]
10. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.
Liu CH; Liu CJ; Hung CC; Hsieh SM; Su TH; Sun HY; Tseng TC; Chen PJ; Chen DS; Kao JH
Liver Int; 2020 Apr; 40(4):758-768. PubMed ID: 31710759
[TBL] [Abstract][Full Text] [Related]
11. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
[TBL] [Abstract][Full Text] [Related]
13. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
Uemura H; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Sugawara K; Nakao M; Motoya D; Nakayama N; Imai Y; Tomiya T; Mochida S
J Gastroenterol; 2019 May; 54(5):459-470. PubMed ID: 30612205
[TBL] [Abstract][Full Text] [Related]
14. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.
Chang KC; Tung SY; Wei KL; Shen CH; Hsieh YY; Chen WM; Chen YH; Chen CH; Yen CW; Xu HW; Tung WL; Hung CH; Lu SN; Chang TS
Sci Rep; 2021 Jun; 11(1):13543. PubMed ID: 34188161
[TBL] [Abstract][Full Text] [Related]
15. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
[TBL] [Abstract][Full Text] [Related]
16. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
Aragri M; Milana M; Di Maio VC; Lenci I; Carioti L; Perno CF; Svicher V; Angelico M; Ceccherini-Silberstein F
Clin Microbiol Infect; 2020 Sep; 26(9):1266-1268. PubMed ID: 32240711
[No Abstract] [Full Text] [Related]
17. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection.
Zhou HJ; Wu G; Li JM; Naidoo N; Xie YX; Feng BL; Wang P; Luo JW
Ann Palliat Med; 2021 Oct; 10(10):10313-10326. PubMed ID: 34670381
[TBL] [Abstract][Full Text] [Related]
19. Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal.
Vera J; Gomes A; Póvoas D; Seixas D; Maltez F; Pedroto I; Maia L; Mota M; Vieira MJ; Manata MJ; Ferreira P; Lino S; Pereira Guedes T; Barradas V; Marques N
Acta Med Port; 2024 May; 37(5):323-333. PubMed ID: 38325411
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C.
Hsu SJ; Chiu MC; Fang YJ; Yang TH; Yu JJ; Chen CC; Kuo CC; Lee JY; Chen CH; Chen DS; Kao JH
J Formos Med Assoc; 2019 Aug; 118(8):1187-1192. PubMed ID: 31279502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
